References:

(1) Rostami-Hodjegan, A. & Tucker, G. `In silico' simulations to assess the `in vivo'
consequences of `in vitro' metabolic drug-drug interactions. Drug Discovery Today:
Technologies 1, 441 (2004).

(2) Galetin, A., Gertz, M. & Houston, J.B. Contribution of intestinal cytochrome P450-
mediated metabolism to drug-drug inhibition and induction interactions. Drug Metab
Pharmacokinet 25, 28-47 (2010).

(3) Fahmi, O.A., Maurer, T.S., Kish, M., Cardenas, E., Boldt, S. & Nettleton, D. A
combined model for predicting CYP3A4 clinical net drug-drug interaction based on
CYP3A4 inhibition, inactivation, and induction determined in vitro. Drug Metab Dispos
36, 1698-708 (2008).

(4) Rowland Yeo, K., Walsky, R.L., Jamei, M., Rostami-Hodjegan, A. & Tucker, G.T.
Prediction of time-dependent CYP3A4 drug-drug interactions by physiologically
based pharmacokinetic modelling: impact of inactivation parameters and enzyme
turnover. Eur J Pharm Sci 43, 160-73 (2011).

(5) Guest, E.J., Aarons, L., Houston, J.B., Rostami-Hodjegan, A. & Galetin, A. Critique of
the two-fold measure of prediction success for ratios: application for the assessment
of drug-drug interactions. Drug Metab Dispos 39, 170-3 (2011).

(6) Rowland Yeo, K., Jamei, M., Yang, J., Tucker, G.T. & Rostami-Hodjegan, A.
Physiologically based mechanistic modelling to predict complex drug-drug
interactions involving simultaneous competitive and time-dependent enzyme
inhibition by parent compound and its metabolite in both liver and gut - the effect of
diltiazem on the time-course of exposure to triazolam. Eur J Pharm Sci 39, 298-309
(2009).

(7) Almond, L.M. et al. Prediction of Drug-Drug Interactions Arising from CYP3A
induction Using a Physiologically Based Dynamic Model. Drug Metab Dispos 44,
821-32 (2016).

(8) Cleary, Y. et al. Model-Based Assessments of CYP-Mediated Drug-Drug Interaction

Risk of Alectinib: Physiologically Based Pharmacokinetic Modeling Supported Clinical
Development. Clin Pharmacol Ther 104, 505-14 (2018).
(9) Jing, X., Ji, P., Schrieber, S.J., Fletcher, E.P. & Sahajwalla, C. Update on Therapeutic
Protein-Drug Interaction: Information in Labeling. Clin Pharmacokinet, (2019). doi:
10.1007/s40262-019-00810-z

1. Barter ZE, Bayliss MK, Beaune PH, Boobis AR, Carlile DJ, Edwards RJ, Houston JB,
Lake BG, Lipscomb JC, Pelkonen OR, Tucker GT, and Rostami-Hodjegan A (2007)
Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro
data: reaching a consensus on values of human microsomal protein and
hepatocellularity per gram of liver. Curr Drug Metab 8:33-45.

2. Gertz M, Harrison A, Houston JB, and Galetin A (2010) Prediction of human intestinal
first-pass metabolism of 25 CYP3A substrates from in vitro clearance and
permeability data. Drug Metab Dispos 38:1147-1158.

3. Kilford, P.J., Gertz, M., Houston, J.B. & Galetin, A. Hepatocellular binding of drugs:
correction for unbound fraction in hepatocyte incubations using microsomal binding or
drug lipophilicity data. Drug Metab Dispos 36, 1194-7 (2008).

4. Hallifax D, Foster JA, and Houston JB (2010) Prediction of human metabolic

clearance from in vitro systems: retrospective analysis and prospective view. Pharm
Res 27:2150-2161.

5. Jones HM, Chen Y, Gibson C, Heimbach T, Parrott N, Peters SA, Snoeys J, Upreti
VV, Zheng M, and Hall SD (2015) Physiologically based pharmacokinetic modeling in
drug discovery and development: a pharmaceutical industry perspective. Clin
Pharmacol Ther 97:247-262.

6. Rostami-Hodjegan A (2012) Physiologically Based Pharmacokinetics Joined With In

Vitro-In Vivo Extrapolation of ADME: A Marriage Under the Arch of Systems
Pharmacology. Clin Pharmacol Ther 92:50-61.

7. Rowland M, Benet LZ, and Graham GG (1973) Clearance concepts in

pharmacokinetics. J Pharmacokinet Biopharm 1:123-136.

8. Gertz, M., Tsamandouras, N., Sall, C., Houston, J.B. & Galetin, A (2014). Reduced
physiologically-based pharmacokinetic model of repaglinide: impact of OATP1B1 and
 CYP2C8 genotype and source of in vitro data on the prediction of drug-drug
interaction risk. Pharm Res 31, 2367-82.

9. Grimstein M, Yang Y, Zhang X, Grillo J, Huang SM, Zineh I, Wang Y (2019).

Physiologically Based Pharmacokinetic Modeling in Regulatory Science: An Update
From the U.S. Food and Drug Administration's Office of Clinical Pharmacology. J
Pharm Sci 108(1):21-25.